| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income - EUR | 1.428 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Expenses - EUR | 4.619 | 2.547 | 1.521 | 5.301 | 1.084 | 0 | 0 | 3.726 | 0 | 0 |
| Gross Profit/Loss - EUR | -3.192 | -2.547 | -1.521 | -5.301 | -1.084 | 0 | 0 | -3.726 | 0 | 0 |
| Net Profit/Loss - EUR | -3.200 | -2.547 | -1.521 | -5.301 | -1.084 | 0 | 0 | -3.726 | 0 | 0 |
| Employees | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 |
Check the financial reports for the company - Meta Quant Lyfe Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 7.814 | 7.419 | 6.997 | 6.584 | 6.269 | 0 | 0 | 6.032 | 6.014 | 0 |
| Current Assets | 66 | 36 | 39 | 700 | 31 | 0 | 0 | -106 | -66 | 0 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 25 | 25 | 24 | 24 | 23 | 0 | 0 | 23 | 22 | 0 |
| Cash | 41 | 12 | 15 | 676 | 8 | 0 | 0 | -128 | -88 | 0 |
| Shareholders Funds | -7.844 | -10.311 | -11.658 | -16.745 | -17.505 | 0 | 0 | -24.374 | -24.300 | 0 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 0 | 0 | 41 | 40 | 0 |
| Debts | 15.725 | 17.766 | 18.694 | 24.029 | 23.804 | 0 | 0 | 30.301 | 30.249 | 0 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4619 - 4619" | |||||||||
| CAEN Financial Year |
9604
|
|||||||||
Comments - Meta Quant Lyfe Srl